NRT was the biggest bulls*& company out. Telling investors of start dates for clinical trials when Anisina had not even started toxicity testing. And cantrixil they had not even and ind and they were handing out dates like fairy flosses. And investor wonder why our current management is so coy. OMG.........
"The study results have led Novogen stock to have a stunning start to the year, with shares in the group rising over 180 per cent over the first 3 months of 2015 to today.
Human trials of Cantrixil are expected to start in late 2015, and the study will mainly target ovarian cancer and colo-rectal cancer. Novogen said its Anisina drug is being brought into the clinic in early 2016 for the treatment of late-stage melanoma and prostate cancer.
"https://www.theaustralian.com.au/bu...y/news-story/54de03a413c6a6da25fcca6073c7d6cb
KZA Price at posting:
43.0¢ Sentiment: Buy Disclosure: Held
